Michael CEREZO

Dr. Michael CEREZO

INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TTT Tomic
T Tomic
TBThomas Botton
Thomas Botton
MCMichael CEREZO
Michael CEREZO
RROBERT Guillaume
ROBERT Guillaume
FLFrederic Luciano
Frederic Luciano
SRStephane Rocchi
Stephane Rocchi
Metformin is the most widely used antidiabetic drug because of its proven efficacy and limited secondary effects. Interestingly, recent studies have reported that metformin can block the growth of different tumor types. Here, we show that metformin exerts antiproliferative effects on melanoma cells, whereas normal human melanocytes are resistant to these metformin-induced effects. To better understand the basis of this antiproliferative effect of metformin in melanoma, we characterized the sequence of events underlying metformin action. We showed that 24 h metformin treatment induced a cell cycle arrest in G0/G1 phases, while after 72 h, melanoma cells underwent autophagy as demonstrated by electron microscopy, immunochemistry, and by quantification of the autolysosome-associated LC3 and Beclin1 proteins. In addition, 96 h post metformin treatment we observed robust apoptosis of melanoma cells. Interestingly, inhibition of autophagy by knocking down LC3 or ATG5 decreased the extent of apoptosis, and suppressed the antiproliferative effect of metformin on melanoma cells, suggesting that apoptosis is a consequence of autophagy. The relevance of these observations were confirmed in vivo, as we showed that metformin treatment impaired the melanoma tumor growth in mice, and induced autophagy and apoptosis markers. Taken together, our data suggest that metformin has an important impact on melanoma growth, and may therefore be beneficial in patients with melanoma.

29 October 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MCMichael CEREZO
Michael CEREZO
RGRamdane Guemiri
Ramdane Guemiri
SDSabine Druillennec
Sabine Druillennec
IGIsabelle Girault
Isabelle Girault
HMHélène Malka-Mahieu
Hélène Malka-Mahieu
Caroline RobertCaroline Robert
Caroline Robert

1 June 2016 in Cancer Cell
Verified
Journal Article
Closed access
MCMichael CEREZO
Michael CEREZO
ALAbdelali Lehraiki
Abdelali Lehraiki
AMAntoine Millet
Antoine Millet
FRFlorian Rouaud
Florian Rouaud
MPMagali Plaisant
Magali Plaisant
SRStephane Rocchi
Stephane Rocchi

1 August 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
MCMichael CEREZO
Michael CEREZO
MTMélanie Tichet
Mélanie Tichet
PAPatricia Abbe
Patricia Abbe
MOMickaël Ohanna
Mickaël Ohanna
ALAbdelali Lehraiki
Abdelali Lehraiki
SRStéphane Rocchi
Stéphane Rocchi
Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells. In this report, we investigated the effect of metformin on melanoma invasion and metastasis development. Using different in vitro approaches, we found that metformin inhibits cell invasion without affecting cell migration and independently of antiproliferation action. This inhibition is correlated with modulation of expression of proteins involved in epithelial–mesenchymal transition such as Slug, Snail, SPARC, fibronectin, and N-cadherin and with inhibition of MMP-2 and MMP-9 activation. Furthermore, our data indicate that this process is dependent on activation of AMPK and tumor suppressor protein p53. Finally, we showed that metformin inhibits melanoma metastasis development in mice using extravasation and metastasis models. The presented data reinforce the fact that metformin might be a good candidate for clinical trial in melanoma treatment. Mol Cancer Ther; 12(8); 1605–15. ©2013 AACR.

30 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMélanie Tichet
Mélanie Tichet
VPVirginie Prod’homme
Virginie Prod’homme
NFNina Fenouille
Nina Fenouille
DADamien Ambrosetti
Damien Ambrosetti
AMAude Mallavialle
Aude Mallavialle
STSophie Tartare-Deckert
Sophie Tartare-Deckert
Disruption of the endothelial barrier by tumour-derived secreted factors is a critical step in cancer cell extravasation and metastasis. Here, by comparative proteomic analysis of melanoma secretomes, we identify the matricellular protein SPARC as a novel tumour-derived vascular permeability factor. SPARC deficiency abrogates tumour-initiated permeability of lung capillaries and prevents extravasation, whereas SPARC overexpression enhances vascular leakiness, extravasation and lung metastasis. SPARC-induced paracellular permeability is dependent on the endothelial VCAM1 receptor and p38 MAPK signalling. Blocking VCAM1 impedes melanoma-induced endothelial permeability and extravasation. The clinical relevance of our findings is highlighted by high levels of SPARC detected in tumour from human pulmonary melanoma lesions. Our study establishes tumour-produced SPARC and VCAM1 as regulators of cancer extravasation, revealing a novel targetable interaction for prevention of metastasis.

15 July 2013 in Cancer Research
Verified
Journal Article
Open access
PDF file
ABAmine Belaid
Amine Belaid
MCMichael CEREZO
Michael CEREZO
ACAbderrahman Chargui
Abderrahman Chargui
ECElisabeth Corcelle–Termeau
Elisabeth Corcelle–Termeau
FPFlorence Pedeutour
Florence Pedeutour
BMBaharia Mograbi
Baharia Mograbi
Degradation of signaling proteins is one of the most powerful tumor-suppressive mechanisms by which a cell can control its own growth. Here, we identify RHOA as the molecular target by which autophagy maintains genomic stability. Specifically, inhibition of autophagosome degradation by the loss of the v-ATPase a3 (TCIRG1) subunit is sufficient to induce aneuploidy. Underlying this phenotype, active RHOA is sequestered via p62 (SQSTM1) within autolysosomes and fails to localize to the plasma membrane or to the spindle midbody. Conversely, inhibition of autophagosome formation by ATG5 shRNA dramatically increases localization of active RHOA at the midbody, followed by diffusion to the flanking zones. As a result, all of the approaches we examined that compromise autophagy (irrespective of the defect: autophagosome formation, sequestration, or degradation) drive cytokinesis failure, multinucleation, and aneuploidy, processes that directly have an impact upon cancer progression. Consistently, we report a positive correlation between autophagy defects and the higher expression of RHOA in human lung carcinoma. We therefore propose that autophagy may act, in part, as a safeguard mechanism that degrades and thereby maintains the appropriate level of active RHOA at the midbody for faithful completion of cytokinesis and genome inheritance. Cancer Res; 73(14); 4311–22. ©2013 AACR.